

PRESS RELEASE

17 November 2023 08:00:00 CET

Saniona's upcoming presentations on November 22 and 23

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that it will present at Økonomisk Ugebrev – Life Science Investor Conference in Copenhagen on November 22 and at Redeye Life Science Day in Stockholm on November 23, 2023. Details are as follows:

CEO Thomas Feldthus will discuss the latest developments at Saniona with an emphasis on the company's intensified focus on epilepsy on November 22 at Økonomisk Ugebrev – Life Science Investor Conference and on November 23 at 13.40 CET at Redeye Life Science Day.

The interview at Redeye Life Science Day can be followed at

<https://www.redeye.se/events/915984/redeye-life-science-day-2023>

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. Saniona's most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity by Saniona's partner Medix. Saniona is advancing four product candidates including Tesomet™ and three ion channel modulators SAN711, SAN903 and SAN2219. Tesomet™ has progressed to mid-stage clinical trials for rare eating disorders. SAN711 has completed Phase 1 for epilepsy. SAN903 is ready for Phase 1 for inflammatory and fibrotic disorders. SAN2219 is in preclinical development for epilepsy. Saniona has research and development partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited and Cephagenix ApS. Saniona is based in Copenhagen, and listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachments

Saniona's upcoming presentations on November 22 and 23